Insulin degludec: pharmacokinetics in patients with renal impairment. - Wikidata - wikimedia - TriplyDB

Insulin degludec: pharmacokinetics in patients with renal impairment.

Insulin degludec: pharmacokinetics in patients with renal impairment.

http://www.wikidata.org/entity/Q37506526

about

Interactions between kidney disease and diabetes: dangerous liaisons The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies Concentrated insulins: the new basal insulins Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes Patient safety and minimizing risk with insulin administration - role of insulin degludec Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.A review of the pharmacological properties of insulin degludec and their clinical relevance.Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.Special considerations for the treatment of chronic kidney disease in the elderly.Clinical use of the co-formulation of insulin degludec and insulin aspart.A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.Current therapeutic approaches in the management of hyperglycemia in chronic renal disease.Degludec: the new ultra-long insulin analogue.Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec.Insulin degludec overdose may lead to long-lasting hypoglycaemia through its markedly prolonged half-life.

P2860

Q26740630-D3565DB5-1001-4837-94F5-E3D37708BCC7 Q26744317-1A2A4CA0-5DC8-4EDE-BE01-2F149EE09072 Q26750438-17B00433-C9AC-4F7F-BE6F-F872DFF91973 Q26766259-E3D95FBA-32BE-44CF-94AB-CBFE52B99DFA Q26778763-CE2BA340-D9FF-460C-B11A-46E2F4594606 Q26784381-A2FEE4A8-4964-447D-91EC-F87682C6315A Q27025548-0A1979D3-7683-4C31-9677-2B80B0162BBC Q31025919-7157A1C2-C30D-479E-8052-BA55D3F71121 Q34436383-710CABAA-7480-4DDC-9732-FB8B66363597 Q36637960-45BA719C-2B43-421B-B1CB-0744276FB1D5 Q37506417-D4A4930A-9092-4CB0-9A8E-062643B0A5A7 Q38241834-B85A4ADB-4B68-4D15-B38E-8FA362CC155F Q38737061-A4F6EC7C-BD4F-4CC9-AC1E-83EA4CAFC913 Q38887939-C5FCDA47-A02C-468F-BFC0-646273F9EF18 Q38970550-77A54008-9926-4A7E-B132-8CF5968B5291 Q39160771-C45CA6D1-D4F3-4285-9246-F39129574338 Q41564970-D8A4C6C6-2568-4F1C-A1F8-99720E02EB65 Q42398691-49F6E5BF-0B00-488D-AFD4-2E0AFE2B2B3B Q48232532-7C933011-41BF-4DFE-9F49-6C71A3B9A224

P2860

Insulin degludec: pharmacokinetics in patients with renal impairment.

http://www.wikidata.org/entity/Q37506526

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Insulin degludec: pharmacokinetics in patients with renal impairment.

@en

Insulin degludec: pharmacokinetics in patients with renal impairment.

@nl

type

label

Insulin degludec: pharmacokinetics in patients with renal impairment.

@en

Insulin degludec: pharmacokinetics in patients with renal impairment.

@nl

prefLabel

Insulin degludec: pharmacokinetics in patients with renal impairment.

@en

Insulin degludec: pharmacokinetics in patients with renal impairment.

@nl

P1433

Q37506526-1EB2F288-7B6F-42B1-ABA1-07E5B4FC1619

P1476

Q37506526-3FA2F461-6C33-4123-B614-93B3AC7AFE66

P2093

Q37506526-1E389AC8-32D1-42D8-B53E-5AE58888641B

Q37506526-234D987B-6B39-4EA7-BEA0-DEDBF44A8DAB

Q37506526-4758CDB6-3D82-4B93-A45D-2BB18A2EF873

Q37506526-920F407D-D89D-4308-876F-1613F603B47A

Q37506526-A327020F-B732-41C5-B59C-7C6A86AFE3B4

Q37506526-E6B5F158-B129-4998-B570-38AF37B19C44

P2860

Q37506526-01FCB78A-C857-4093-81AC-D4ADEEF5D886

Q37506526-13453BF2-CABC-473D-9394-82FCEE9FF6D6

Q37506526-17BDDF45-AE00-4539-873F-1D2DA5793A70

Q37506526-1B9D6140-180E-42B9-9B5B-68B4C016B365

Q37506526-21282FCA-EC0F-4611-9DA1-6165D62B1E88

Q37506526-249ED7C0-3525-44BB-A3AE-BABAF058D892

Q37506526-285088A4-1AB2-4EFC-A221-B2F9B336D553

Q37506526-2A1F8132-2682-429F-95B5-CE70D628BC71

Q37506526-4A53EA01-290E-44DB-8D56-25EE1F5B8FE4

Q37506526-4E6C8F28-7726-44A1-B485-A3E5D6859A93

P2888

Q37506526-F95D10BF-90D1-466A-9F6F-6DA88738F08F

P304

Q37506526-4BFF5105-3233-467F-A910-593389C2BDA0

P31

Q37506526-8E2A79AD-EC44-4854-A069-BE2A127439E1

P356

Q37506526-9A3D9EA9-0A45-4326-AD1E-BE7753C0AE47

P433

Q37506526-EA1826F8-4819-4C98-9DA4-FF3C3310C73C

P478

Q37506526-15B71CBB-F9E5-49D4-9921-3A081F93766A

P577

Q37506526-D7D94268-1D13-4793-81E9-1229C4FCE788

P5875

Q37506526-75D6FB38-E0DC-44FC-9D2D-BF168CE5EA99

P698

Q37506526-5AD0B6FA-7207-4A8B-98C5-348744B34B43

P921

Q37506526-426FCD5F-45DE-4030-AA2E-661A4E6FA381

P932

Q37506526-36B8ED58-B1DA-4BB2-A031-3DB3DAEA1AC9

P356

S40262-013-0113-2

P1433

Clinical Pharmacokinetics

P1476

Insulin degludec: pharmacokinetics in patients with renal impairment.

@en

P2093

Carsten Roepstorff

http://www.w3.org/2001/XMLSchema#string

Gerhard Arold

http://www.w3.org/2001/XMLSchema#string

Hanne Haahr

http://www.w3.org/2001/XMLSchema#string

István Kiss

http://www.w3.org/2001/XMLSchema#string

Susanne Gammelgaard Bøttcher

http://www.w3.org/2001/XMLSchema#string

Søren Klim

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes.

Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.

Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease.

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency.

Risk factors for inpatient hypoglycemia during subcutaneous insulin therapy in non-critically ill patients with type 2 diabetes.

Temporal trends in the prevalence of diabetic kidney disease in the United States

P2888

s40262-013-0113-2

P304

175-183

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-013-0113-2

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258104077

http://www.w3.org/2001/XMLSchema#string

P698

24163264

http://www.w3.org/2001/XMLSchema#string

P921

P932

3899495

http://www.w3.org/2001/XMLSchema#string